Clonal hematopoiesis driven atherosclerosis is mitigated by CD45-ADC and HSCT. (A) Representative flow plots showing the degree of CFP chimerism in atherosclerotic aortic lesions, 16 weeks after transplantation into Ldlr KO mice. (B) Bar graphs showing flow cytometric analysis of CD45.1 chimerism, 6 weeks after CD45-ADC treatment, and CD45.1⁺ HSCT in atherosclerotic Ldlr KO mice with either WT or Tet2 KO bone marrow. (C) Flow plots representative of atherosclerotic aortic lesion CD45.1 chimerism after CD45-ADC treatment, and CD45.1⁺ HSCT in Ldlr KO mice with either WT or Tet2 KO bone marrow. (D-G) Absolute numbers of various myeloid immune cells in aortic atherosclerotic plaques, 6 weeks after CD45-ADC treatment, and CD45.1⁺ HSCT in Ldlr KO mice with either WT or Tet2 KO bone marrow, as analyzed by flow cytometry.